title: A prospective, randomized controlled preclinical trial to evaluate different formulations of biphasic calcium phosphate in combination with a hydroxyapatite collagen membrane to reconstruct deficient alveolar ridges.
abstract: Many patients and clinicians would prefer a synthetic particulate bone replacement graft, but most available alloplastic biomaterials have limited osteogenic potential. An alloplast with increased regenerative capacity would be advantageous for the treatment of localized alveolar ridge defects. This prospective, randomized controlled preclinical trial utilized 6 female foxhounds to analyze the osteogenic impact of different formulations of biphasic calcium phosphate (BCP) in combination with an hydroxyapatite-collagen membrane and their ability to reconstruct deficient alveolar ridges for future implant placement. The grafted sites were allowed to heal 3 months, and then trephine biopsies were obtained to perform light microscopic and histomorphometric analyses. All treated sites healed well with no early membrane exposure or adverse soft tissue responses during the healing period. The grafted sites exhibited greater radiopacity than the surrounding native bone with BCP particles seen as radiopaque granules. The graft particles appeared to be well-integrated and no areas of loose particles were observed. Histologic evaluation demonstrated BCP particles embedded in woven bone with dense connective tissue/marrow space. New bone growth was observed around the graft particles as well as within the structure of the graft particulate. There was intimate contact between the graft particles and newly formed bone, and graft particles were bridged by the newly formed bone in all biopsies from the tested groups. The present study results support the potential of these BCP graft particulates to stimulate new bone formation. Clinical studies are recommended to confirm these preclinical findings.
authors.affiliation: Department of Oral Medicine, Harvard School of Dental Medicine, Boston, MA, USA.
authors.forename: Myron
authors.initials: M
authors.lastname: Nevins
authors.forename: Marc L
authors.initials: ML
authors.lastname: Nevins
authors.forename: Peter
authors.initials: P
authors.lastname: Schupbach
authors.forename: Soo-Woo
authors.initials: SW
authors.lastname: Kim
authors.forename: Zhao
authors.initials: Z
authors.lastname: Lin
authors.forename: David M
authors.initials: DM
authors.lastname: Kim
mesh_terms: D000540:Alveolar Ridge Augmentation / Q000379:methods*; D000818:Animals; D001706:Biopsy; D001857:Bone Matrix / Q000473:pathology; D001861:Bone Regeneration / Q000502:physiology; D018786:Bone Substitutes / Q000737:chemistry* / Q000627:therapeutic use; D002516:Ceramics / Q000737:chemistry*; D002626:Chemistry, Pharmaceutical; D003094:Collagen / Q000737:chemistry*; D004285:Dogs; D017886:Durapatite / Q000737:chemistry*; D005260:Female; D006882:Hydroxyapatites / Q000737:chemistry* / Q000627:therapeutic use; D008334:Mandible / Q000000981:diagnostic imaging / Q000473:pathology / Q000601:surgery*; D008567:Membranes, Artificial; D016348:Osseointegration / Q000502:physiology; D010006:Osteoblasts / Q000473:pathology; D010012:Osteogenesis / Q000502:physiology; D011446:Prospective Studies; D011859:Radiography; D011897:Random Allocation; D019651:Plastic Surgery Procedures / Q000379:methods; D013499:Surface Properties; D014945:Wound Healing / Q000502:physiology
chemical_list: D018786:Bone Substitutes; D006882:Hydroxyapatites; D008567:Membranes, Artificial; C074950:hydroxyapatite-beta tricalcium phosphate; D003094:Collagen; D017886:Durapatite